Latest & greatest articles for rivaroxaban

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rivaroxaban or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rivaroxaban and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rivaroxaban

41. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Full Text available with Trip Pro

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices (...) -in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2·5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction

2017 Lancet Controlled trial quality: predicted high

42. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. (Abstract)

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of platelets and coagulation proteins. Factor Xa inhibitors and aspirin each reduce thrombotic events but have not yet been tested in combination or against each other in patients with stable (...) , previous multi-vessel percutaneous coronary intervention, or previous multi-vessel coronary artery bypass graft surgery. After a 30-day run in period, patients were randomly assigned (1:1:1) to receive rivaroxaban (2·5 mg orally twice a day) plus aspirin (100 mg once a day), rivaroxaban alone (5 mg orally twice a day), or aspirin alone (100 mg orally once a day). Randomisation was computer generated. Each treatment group was double dummy, and the patients, investigators, and central study staff were

2017 Lancet Controlled trial quality: predicted high

43. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. Full Text available with Trip Pro

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention.In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome (...) was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months.The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=-4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus

2017 NEJM Controlled trial quality: predicted high

44. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. Full Text available with Trip Pro

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin.In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had completed 6 to 12 (...) of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group

2017 NEJM Controlled trial quality: predicted high

45. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Full Text available with Trip Pro

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard antithrombotic treatment following acute coronary syndromes. The factor Xa inhibitor rivaroxaban reduced mortality and ischaemic events when added to DAPT, but caused increased bleeding. The safety of a dual pathway (...) antithrombotic therapy approach combining low-dose rivaroxaban (in place of aspirin) with a P2Y12 inhibitor has not been assesssed in acute coronary syndromes. We aimed to assess rivaroxaban 2·5 mg twice daily versus aspirin 100 mg daily, in addition to clopidogrel or ticagrelor (chosen at investigator discretion before randomisation), for patients with acute coronary syndromes started within 10 days after presentation and continued for 6-12 months.In this double-blind, multicentre, randomised trial (GEMINI

2017 Lancet Controlled trial quality: predicted high

46. Cohort study: Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation

Cohort study: Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation Article

2017 Evidence-Based Medicine

47. The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial (Abstract)

The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial Tranexamic acid (TXA) was reportedly to decrease postoperative blood loss after standard total knee arthroplasty (TKA). However, the blood-conservation effect of TXA in minimally invasive TKA, in particular, receiving a direct oral anticoagulant was unclear. The aim of the study was to investigate the efficacy of combined (...) use of TXA and rivaroxaban on postoperative blood loss in primary minimally invasive TKA.In a prospective, randomized, controlled trial, 198 patients were assigned to placebo (98 patients, normal saline injection) and study group (100 patients, 1g TXA intraoperative injection) during primary unilateral minimally invasive TKA. All patients received rivaroxaban 10 mg each day for 14 doses postoperatively. Total blood loss was calculated from the maximum hemoglobin drop after surgery plus amount

2016 EvidenceUpdates

48. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States Full Text available with Trip Pro

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States Limited data are available about the real-world safety of non-vitamin K antagonist oral anticoagulants (NOACs).To compare the major bleeding risk among newly anticoagulated non-valvular atrial fibrillation (NVAF) patients initiating apixaban, warfarin, dabigatran or rivaroxaban in the United States.A retrospective (...) cohort study was conducted to compare the major bleeding risk among newly anticoagulated NVAF patients initiating warfarin, apixaban, dabigatran or rivaroxaban. The study used the Truven MarketScan(®) Commercial & Medicare supplemental US database from 1 January 2013 through 31 December 2013. Major bleeding was defined as bleeding requiring hospitalisation. Cox model estimated hazard ratios (HRs) of major bleeding were adjusted for age, gender, baseline comorbidities and co-medications. Among 29 338

2016 EvidenceUpdates

49. Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis? Full Text available with Trip Pro

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis? Venous thromboembolic events (VTEs) are common and potentially fatal complications in cancer patients, and they are responsible for the second most common cause of death. Low molecular weight heparin (LMWH) is the gold-standard treatment, but the costs involved limit its use, especially in developing countries. Recently, the oral anticoagulant rivaroxaban, which directly inhibits factor Xa, was approved for VTE (...) treatment.We conducted a retrospective analysis from January 2009 to February 2014 with patients who had cancer and VTE who were receiving rivaroxaban. We compared the efficacy, safety, and cost of rivaroxaban and low molecular weight heparin (LMWH) alone or followed by vitamin K antagonists.Forty-one patients were identified, with a median age of 62.5 years. The most frequent tumor histology was adenocarcinoma (78%), which was most often found in the colon (26.8%). Most participants had advanced disease

2016 Journal of global oncology

50. Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding Full Text available with Trip Pro

Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding Outpatient treatment of acute venous thromboembolism (VTE) requires the selection of patients with a low risk of bleeding during the first few weeks of anticoagulation. The accuracy of four systems, originally derived for predicting bleeding in VTE treated with vitamin K antagonists (VKAs), was assessed in VTE patients treated with rivaroxaban.All patients (...) treated with rivaroxaban in the multinational EINSTEIN deep vein thrombosis (DVT) and pulmonary embolism (PE) trials were included. Major bleeding was defined as ≥2 g/dL drop in hemoglobin or ≥2-unit blood transfusion, bleeding in critical area, or bleeding contributing to death. The authors examined the incidence of major bleeding in patients with low-risk assignment by the systems of Ruiz-Gimenez et al. (score = 0 to 1), Beyth et al. (score = 0), Kuijer et al. (score = 0), and Landefeld and Goldman

2016 EvidenceUpdates

51. Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning Full Text available with Trip Pro

Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning Direct oral anticoagulants (DOACs or NOACs -non-vitamin K oral anticoagulants), as the name suggests, are oral anticoagulants with a direct inhibitory action either against factor X or factor II (thrombin). Pregnant women were excluded from participating in all the large trials of the DOACs and they are considered contra-indicated in pregnancy and breast feeding. We present a case of inadvertent exposure to rivaroxaban

2015 Obstetric medicine

52. Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months?

Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? BestBets: Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Report By: Chris Morgan - Medical Student Y5 Search checked by Rick Body - Consultant in Emergency Medicine Institution: University of Manchester, Manchester, UK Original institution: Manchester Royal Infirmary Date Submitted: 21st October 2015 (...) Date Completed: 21st October 2015 Last Modified: 21st October 2015 Status: Green (complete) Three Part Question In [patients with proven pulmonary embolism (PE)] is [Rivaroxaban better than warfarin] at [reducing mortality and recurrence of venous thromboembolism at 6 months]? Clinical Scenario A 52-year-old lady has presented to the Emergency Department with a suspected PE. This is confirmed by CT pulmonary angiography (CTPA). Consequently she requires anticoagulation. Hospital guidelines suggest

2015 BestBETS

53. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation Full Text available with Trip Pro

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation VENTURE-AF is the first prospective randomized trial of uninterrupted rivaroxaban and vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation (CA).Trial size was administratively set at 250, the protocol-specified target. Events were independently and blindly adjudicated. We randomly assigned 248 NVAF patients (...) to uninterrupted rivaroxaban (20 mg once-daily) or to an uninterrupted VKA prior to CA and for 4 weeks afterwards. The primary endpoint was major bleeding events after CA. Secondary endpoints included thromboembolic events (composite of stroke, systemic embolism, myocardial infarction, and vascular death) and other bleeding or procedure-attributable events. Patients were 59.5 ± 10 years of age, 71% male, 74% paroxysmal AF, and had a CHA2DS2-VASc score of 1.6. The average total heparin dose used to manage

2015 EvidenceUpdates Controlled trial quality: predicted high

54. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study Full Text available with Trip Pro

Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study The objective was to assess adverse outcomes in relation to the simplified Pulmonary Embolism Severity Index (PESI) score in patients treated with rivaroxaban or standard therapy in the phase III EINSTEIN PE study and to evaluate the utility of the simplified PESI score to identify low-risk pulmonary embolism (PE) patients.A post hoc (...) analysis of EINSTEIN PE data was performed to assess the efficacy and safety of rivaroxaban in patients with a range of simplified PESI scores. Recurrent venous thromboembolism, fatal PE, all-cause mortality, and major bleeding were stratified by simplified PESI scores of 0, 1, or ≥2 and according to treatment period at 7, 14, 30, and 90 days and at the end of the full intended treatment period.Simplified PESI scores could be calculated in 4,831 of the 4,832 randomized patients; of those, 53.6, 36.7

2015 EvidenceUpdates Controlled trial quality: uncertain

55. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in (Abstract)

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Digoxin is a widely used drug for ventricular rate control in patients with atrial fibrillation (AF), despite a scarcity of randomised trial data. We studied the use and outcomes of digoxin in patients in the Rivaroxaban Once Daily Oral Direct

2015 Lancet

56. Rivaroxaban (Xarelto)

Rivaroxaban (Xarelto) © 2015 Thrombosis Canada Page 1 of 3 RIVAROXABAN (XARELTO ? ) OBJECTIVE: To provide an overview of the mechanism of action, licensed indications, dosing regimens and side- effects for rivaroxaban. BACKGROUND: Rivaroxaban (Xarelto ? ) is an oral factor Xa inhibitor. By binding reversibly to the active site of factor Xa, rivaroxaban attenuates thrombin generation and reduces fibrin formation. INDICATIONS: Rivaroxaban is currently licensed in Canada for: ? Thromboprophylaxis (...) thereafter. ? Rivaroxaban should not be used in patients with a CrCl 50 mL/min or 15 mg OD for those with CrCl 30-49 mL/min. MONITORING: Routine laboratory monitoring is unnecessary. Although the prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT) do not provide reliable measures of rivaroxaban’s anticoagulant activity, the prothrombin time is more responsive. Anti- factor Xa assays using rivaroxaban calibrators, where available, can be used

2015 Thrombosis Interest Group of Canada

57. In nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age Full Text available with Trip Pro

In nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age 25402538 2015 04 14 2018 12 02 1539-3704 161 10 2014 Nov 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: in nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age. JC5 10.7326/0003-4819-161-10-201411180-02005 Rondina Matthew M eng K23 HL092161 HL NHLBI NIH HHS United States R01 AG048022 AG NIA NIH HHS United

2014 Annals of Internal Medicine

58. Rivaroxaban 2.5 mg (Xarelto): no justification for using this anticoagulant after an acute coronary syndrome

Rivaroxaban 2.5 mg (Xarelto): no justification for using this anticoagulant after an acute coronary syndrome Prescrire IN ENGLISH - Spotlight ''Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome'', 1 October 2014 {1} {1} {1} | | > > > Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |  (...)  |   |   |   |   |   |   |   |  Spotlight Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome FEATURED REVIEW It has not been demonstrated that adding rivaroxaban to aspirin alone or to aspirin plus clopidogrel benefits patients who have had an acute coronary syndrome. The risk of serious and fatal bleeds is probably underestimated. Caution dictates that rivaroxaban should

2014 Prescrire

59. Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety

Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Apixaban and rivaroxaban for stroke (...) prevention in atrial fibrillation: safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Reference List. 2014 Authors' conclusions Twenty-two systematic reviews/meta-analyses, 24 randomized controlled trials, and three non-randomized studies were identified regarding adverse events associated with the use of apixaban and rivaroxaban. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anticoagulants; Atrial Fibrillation; Humans; Morpholines

2014 Health Technology Assessment (HTA) Database.

60. Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism

Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism (...) . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions CDEC recommends that rivaroxaban be listed for the treatment of VTE (DVT and PE) and prevention of recurrent DVT and PE, for a duration of up to six months. If treatment is to be extended beyond six months, the following condition must be met. Condition: A reduction in price is required if rivaroxaban is funded for a treatment duration of more than six months. Final publication

2014 Health Technology Assessment (HTA) Database.